OOIR: Observatory of International Research

Papers

(The TQCC of Experimental Hematology & Oncology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity	292
Inhibition of EYA family tyrosine phosphatase activity reveals a therapeutic vulnerability and enhances Menin and DOT1L inhibitor efficacy in KMT2A-rearranged leukemia	213
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	212
MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting	175
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	153
Correction: The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma	144
From Amphiphiles to mRNA platforms: emerging vaccination strategies for pancreatic cancer	137
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	133
Tertiary lymphoid structures correlate with reduced recurrence risk and enhanced antitumor immunity in esophageal squamous cell carcinoma with pathologic non-complete response to neoadjuvant chemoimmu	127
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	126
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	117
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	114
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms	104
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	103
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	99
Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy	98
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	96
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	93
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	85
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	82
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	79
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	79
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	75
Tetrahydromagnolol targets TRIM38 to mediate PANoptosis in cancer cells and has the potential for synergistic cancer therapy	75
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	68

Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	66
Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis	65
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	59
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	59
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	58
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	56
ISX–TWIST1 reprograms CD47–inflammasome signaling to reshape the immune microenvironment in liver cancer	55
Role of m6A writers, erasers and readers in cancer	54
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	54
Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting	54
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	54
Breast cancer heterogeneity and its implication in personalized precision therapy	54
Three-dimensional chromatin landscapes in MLLr AML	52
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma	52
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	51
The novel retinoid WYC-209 sensitizes multiple myeloma to carfilzomib via epigenetically upregulating ZMYND8	51
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	50
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	49
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma	48
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells	48
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma	48
Arsenic trioxide promotes a glue‑like interaction to drive STUB1-mediated NPM-ALK degradation in ALK+ ALCL	47
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination	46
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia	44
Correction: Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	44
Metabolic drivers of genome instability in cancer: mechanisms and therapeutic opportunities	43
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs	42
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes	42
Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells	42
Matrix stiffness induces Ca2+-DCLK1-PIP5K1A mechanotransduction as a context-specific amplifier in pancreatic cancer progression and chemotherapy resistance	42
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis	41
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response	41
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma	41
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma	40
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances	40
Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy	39
Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma	39
KMT2A alterations in acute myeloid leukemia: a proposed genetic risk model and transplantation outcomes	38
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors	37
Recent advances and future perspectives in the therapeutics of prostate cancer	37
Disparities in the incidence, mortality and disability-adjusted life years of 33 early-onset cancer groups globally, 2012–2021: a systematic analysis	36
Crosstalk between O-GlcNAcylation and ubiquitination: a novel strategy for overcoming cancer therapeutic resistance	36
A one-base therapeutic insertion in the HBG2 distal promoter reactivates γ-globin expression	36
Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study	36
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential	35
The clinical impact of IKZF1 mutation in acute myeloid leukemia	35
Immunotherapy in breast cancer: current landscape and emerging trends	35
Antibody-drug conjugates in breast cancer: current evidence and future directions	35
Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights	35
Versatile function of NF-ĸB in inflammation and cancer	34

New exploration of KRASG12D inhibitors and the mechanisms of resistance	33
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review	33
Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy	32
Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia	31
Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms	31
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma	31
Engineered extracellular vesicles displaying bi-specific T-cell engagers for targeted therapy of B-cell malignancies	30
Decoding the spatiotemporal characteristics of ferroptosis: reshaping tumour therapeutic strategies	30
FGL1-mediated lymph node metastasis in stage T1 non-small cell lung cancer: therapeutic targeting	30
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity	29
Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	29
Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study	29
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma	28
A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia	28
Downregulation of pro-surfactant protein B contributes to the recurrence of early-stage non-small cell lung cancer by activating PGK1-mediated Akt signaling	28
Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer	28
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications	28
CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy	28
Validation of a microRNA profile in urine liquid biopsy with diagnostic and stratification value for bladder cancer classification, available through the open app BladdermiRaCan	28
Sarcosine sensitizes lung adenocarcinoma to chemotherapy by dual activation of ferroptosis via PDK4/PDHA1 signaling and NMDAR-mediated iron export	27
Efficacy of melflufen in multiple myeloma with mutated or deleted TP53	27
Obesity- and tumor-derived signals drive cancer-associated state transitions in breast mesenchymal stromal/stem cells reprogrammed by IL1RA or JAK inhibition	27
Incidence, mortality, and risk factors of bladder, kidney, prostate and testicular cancers in China and comparisons with the United States, the United Kingdom, Japan, and the Republic of Korea: an up-	27
Immunotherapy in chronic lymphocytic leukemia: advances and challenges	27
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting	27
DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia	27
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis	26
The roles of tissue resident macrophages in health and cancer	26
Role of methionine metabolism in cancer: recent advances in molecular mechanisms and therapeutic implications	26
Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	26
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment	26
Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy	25
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma	25
Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA	24
An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo	23
Bladder cancer subtypes exhibit limited plasticity across different microenvironments and in metastases	23
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies	23
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities	23
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications	22
In-depth insight into tumor-infiltrating stromal cells linked to tertiary lymphoid structures and their prospective function in cancer immunotherapy	22
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA	22
Molecular background of Philadelphia chromosome dependent enhancement of cellular growth and tyrosine kinase inhibitor sensitivity	22
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies	22
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma	22
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates	22
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies	22
Epigenetic and post-translational regulatory networks of ferroptosis in the tumor immune microenvironment	22
Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolution	22
Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance	22
In vivo CAR-T engineering: insights from the 2025 ASH annual meeting	22
Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	22
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer	21
Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesicles	21
Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults	21
Anti-tumor vaccine efficacy depends on adjuvant type and associates with induced IgG subclass and glycosylation profiles	21
Crosstalk between ferroptosis and extracellular vesicles in cancer: from interaction to clinical application	21